KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $808.4 million.

  • Pacira BioSciences' Non-Current Assets fell 11.65% to $734.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $734.8 million, marking a year-over-year decrease of 11.65%. This contributed to the annual value of $808.4 million for FY2024, which is 24.05% down from last year.
  • Pacira BioSciences' Non-Current Assets amounted to $808.4 million in FY2024, which was down 24.05% from $1.1 billion recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' Non-Current Assets peaked at $1.2 billion during FY2021, and registered a low of $622.9 million during FY2020.
  • For the 3-year period, Pacira BioSciences' Non-Current Assets averaged around $1.0 billion, with its median value being $1.1 billion (2023).
  • Its Non-Current Assets has fluctuated over the past 5 years, first spiked by 94.14% in 2021, then dropped by 24.05% in 2024.
  • Over the past 5 years, Pacira BioSciences' Non-Current Assets (Yearly) stood at $622.9 million in 2020, then skyrocketed by 94.14% to $1.2 billion in 2021, then decreased by 2.19% to $1.2 billion in 2022, then dropped by 10.02% to $1.1 billion in 2023, then fell by 24.05% to $808.4 million in 2024.